Evidence map›Paper›PMID 34660302›Full record

ArticleFrontiers in oncology2021

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer.

Sungchan Gwark, Woo Chul Noh, Sei Hyun Ahn, Eun Sook Lee, Yongsik Jung, Lee Su Kim, Wonshik Han, Seok Jin Nam, Gyungyub Gong, Seon-Ok Kim and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01622361 (A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01622361 phase3unknown statusnot on this map

A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer

TypeinterventionalSponsorAsan Medical CenterRan2012 to 2016Enrolled290ConditionsBreast CancerArmsAdriamycin+Cyclophosphamide>Docetaxel, GnRHa with Tamoxifen
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Sungchan GwarkDepartment of Surgery, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, South Korea.
Woo Chul NohDepartment of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
Sei Hyun AhnDepartment of Surgery, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, South Korea.
Eun Sook LeeDepartment of Surgery, Center for Breast Cancer, Research and Institute and Hospital, National Cancer Center, Goyang, South Korea.
Yongsik JungDepartment of Surgery, School of Medicine, Ajou University, Suwon, South Korea.
Lee Su KimDivision of Breast and Endocrine Surgery, College of Medicine, Hallym Sacred Heart Hospital, Hallym University, Anyang, South Korea.
Wonshik HanDepartment of Surgery and Cancer Research Institute, College of Medicine, Seoul National University, Seoul, South Korea.
Seok Jin NamDepartment of Surgery, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea.
Gyungyub GongDepartment of Pathology, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, South Korea.
Seon-Ok KimDepartment of Clinical Epidemiology and Biostatistics, Asan Medical Center, Seoul, South Korea.
Hee Jeong KimDepartment of Surgery, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, South Korea.
Asan Medical Center · KRAjou University · KRHallym University Sacred Heart Hospital · KRKorea Institute of Radiological and Medical Sciences · KRNational Cancer Center · KRSamsung Medical Center · KRSeoul National University · KRUniversity of Ulsan · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we aimed to evaluate axillary lymph node dissection (ALND) rates and prognosis in neoadjuvant chemotherapy (NCT) compare with neoadjuvant endocrine therapy (NET) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), lymph node (LN)-positive, premenopausal breast cancer patients (NCT01622361). The multicenter, phase 3, randomized clinical trial enrolled 187 women from July 5, 2012, to May 30, 2017. The patients were randomly assigned (1:1) to either 24 weeks of NCT including adriamycin plus cyclophosphamide followed by intravenous docetaxel, or NET involving goserelin acetate and daily tamoxifen. ALND was performed based on the surgeon's decision. The primary endpoint was ALND rate and surgical outcome after preoperative treatment. The secondary endpoint was long-term survival. Among the 187 randomized patients, pre- and post- neoadjuvant systemic therapy (NST) assessments were available for 170 patients. After NST, 49.4% of NCT patients and 55.4% of NET patients underwent mastectomy after treatment completion. The rate of ALND was significantly lower in the NCT group than in the NET group (55.2% CLINICAL

trial registrationhttps://clinicaltrials.gov/ct2/show/NCT01622361, identifier NCT01622361.

Indexed as

axillary lymph node dissectionHER2-negativelymph node-positive breaST (NEST)neoadjuvant chemotherapyneoadjuvant endocrine therapyneoadjuvant study of chemotherapy versus Endocrine therapy in premenopausal patient with hormone responsiveprognosissurvival

Identifiers

PMID34660302
PMCPMC8515848
OpenAlexW3204646977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.